ELTX Stock — Elicio Therapeutics Inc.

Elicio Therapeutics Inc. (ELTX)

Updated October 16, 2026.

ELTX is a Stock. Total return is -99.1% over the past 5.7 years, 211.6 points behind SPY at 112.5%.

Elicio Therapeutics is a clinical-stage biotechnology company developing immunotherapy treatments for cancer, with its lead candidate ELI-002 in Phase II trials for tumors driven by KRAS mutations, along with earlier-stage programs targeting BRAF and p53-mutated cancers. The company does not currently have an established distribution schedule. This security may appeal to investors with a high risk tolerance interested in early-stage oncology research and development.

ELTX performance versus SPY

Price and return data through 2026-10-16.

Total return is -99.1% over the past 5.7 years, 211.6 points behind SPY at 112.5%. Over the past year its total return — price change plus distributions reinvested — is -84.5%. Its deepest 1-year drawdown was 89.5%.

ELTX key facts

Asset type

Stock

Asset class

Equity

Inception date

02/05/2021

Distribution frequency

None

Last close

$1.56 (as of 2026-10-16)

Market cap

$40,999,736

Average volume

333446.0

Beta

1.977

Payout ratio

0.0%

EPS

$-2.16

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

ELTX risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 89.5%.

Who may consider ELTX — and who may not

It is a weaker fit for investors who need monthly cash flow (ELTX does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on ELTX

• All tickers starting with E

Tagged: Healthcare.

Frequently asked questions